Roche inks $15B ADC pact with Hansoh; Veradermics scores in another baldness study
PartnershipPositive
AI Analysis
Summary
Roche is paying Hansoh $400 million up front in a deal involving several ADCs, with a headline value of up to $15 billion. The newsletter also notes Veradermics' positive results in another baldness study, a new China-focused investor fund, and Ultragenyx's sale of a second priority review voucher.
Outcome Details
Roche to pay Hansoh $400 million up front in a broad deal involving several antibody-drug conjugates (ADCs); headline cites a total deal value of $15B.
Importance:8/10
Sentiment:
0.50
ADClicensingpartnershipChinaRocheHansohpriority review voucherUltragenyxVeradermicsalopecia
Read the original article
Published by BioPharma Dive on October 19, 2026 1:14 PM